CD274 and head and neck squamous cell carcinoma: Inclusion criteria include R/M HNSCC (oral cavity, oropharynx, hypopharynx, or larynx) that have progressed during or after treatment with anti-PD-1, anti-PD-L1 or anti-CTLA4 monotherapy.